Rachael A. Potter

1.2k citations

30 papers · 667 indexed · 1 hit paper · h-index 11

Genetics top 10%
- Virus-based gene therapy research 15
- Neurogenetic and Muscular Disorders Research 3
Genetics top 10%
- Virus-based gene therapy research 15
- Neurogenetic and Muscular Disorders Research 3
Molecular Biology
- Muscle Physiology and Disorders 27
Cardiology and Cardiovascular Medicine top 10%
- Viral Infections and Immunology Research 4
Cellular and Molecular Neuroscience
Surgery
- Tissue Engineering and Regenerative Medicine 6
Oncology
- CAR-T cell therapy research 6
Biomedical Engineering
- Prosthetics and Rehabilitation Robotics 3
Rheumatology
- GDF15 and Related Biomarkers 3

Co-authors: Louise R. Rodino‐Klapac Danielle A. Griffin Jerry R. Mendell Kelly J. Lehman Eric R. Pozsgai Sarah Lewis Zarife Sahenk Linda Lowes
Cited by: Genetics Molecular Biology
Journals: Nature Medicine (1 paper)SHILAP Revista de lepidopterología (1 paper)Neurology (6 papers)
Partner nations: United States Switzerland United Kingdom

In The Last Decade

Rachael A. Potter

30 papers receiving 655 citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Rachael A. Potter

Since Specialization

Citations

This map shows the geographic impact of Rachael A. Potter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachael A. Potter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachael A. Potter more than expected).

Fields of papers citing papers by Rachael A. Potter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachael A. Potter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachael A. Potter. The network helps show where Rachael A. Potter may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Rachael A. Potter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rachael A. Potter Line = papers co-authored together Rachael A. Potter links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy Scientific Reports ·Rachael A. Potter,Ida Moeller,Sohrab Khan,Hélène Haegel,Andreas Hollenstein,Guido Steiner,Christoph Wandel,Alexander P. Murphy,Damon R. Asher,Emanuel Palatinsky,Danielle A. Griffin,Stefanie Mason,Susan T. Iannaccone,Craig M. Zaidman,Louise R. Rodino‐Klapac	2025	8
2	Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMD ^MDX Rats Human Gene Therapy ·Stephen Baine,Chris Wier,Luke R. Lemmerman,Grace Cooper-Olson,Amber Kempton,Alex Haile,Julian Endres,Alessandra Fedoce,Emily Nesbit,Louise R. Rodino‐Klapac,Rachael A. Potter	2024	5
3	Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74 Molecular Therapy — Methods & Clinical Development ·Rachael A. Potter,Ellyn L. Peterson,Danielle Griffin,Grace Cooper Olson,Sarah Lewis,Kyle Cochran,Jerry R. Mendell,Louise R. Rodino‐Klapac	2024	19
4	Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results Nature Medicine ·Jerry R. Mendell,Eric R. Pozsgai,Sarah Lewis,Danielle A. Griffin,Linda Lowes,Lindsay N. Alfano,Kelly J. Lehman,Kathleen Church,Natalie F. Reash,M. Iammarino,Brenna Sabo,Rachael A. Potter,Sarah Neuhaus,Xiaoxi Li,Herb Stevenson,Louise R. Rodino‐Klapac	2024	9
5	Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR) Annals of Neurology ·Craig M. Zaidman,Crystal M. Proud,Craig M. McDonald,Kelly J. Lehman,Natalie L. Goedeker,Stefanie Mason,Alexander P. Murphy,Maitea Guridi,Shufang Wang,Carol Reid,Eddie Darton,Christoph Wandel,Sarah Lewis,Jyoti Malhotra,Danielle A. Griffin,Rachael A. Potter,L. Rodino-Klapac,Jerry R. Mendell	2023	47
6	Expression and function of four AAV-based constructs for dystrophin restoration in the mdx mouse model of Duchenne muscular dystrophy Biology Open ·Rachael A. Potter,Danielle A. Griffin,Kristin N. Heller,Jerry R. Mendell,Louise R. Rodino‐Klapac	2023	1
7	Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial Muscle & Nerve ·Jerry R. Mendell,Zarife Sahenk,Kelly J. Lehman,Linda Lowes,Natalie F. Reash,M. Iammarino,Lindsay N. Alfano,Sarah Lewis,Kathleen Church,Richard Shell,Rachael A. Potter,Danielle A. Griffin,Mark Hogan,Shufang Wang,Stefanie Mason,Eddie Darton,Louise R. Rodino‐Klapac	2023	37
8	P314: Long-term safety and sustained functional benefit in patients with DMD 4 years post-treatment with delandistrogene moxeparvovec: A phase 1/2a study* SHILAP Revista de lepidopterología ·Erin O’Rourke,Jerry R. Mendell,Zarife Sahenk,Kelly J. Lehman,Linda Lowes,Natalie F. Reash,M. Iammarino,Lindsay N. Alfano,Sarah J. Lewis,Kathleen Church,Richard Shell,Rachael A. Potter,Danielle Griffin,Mark Hogan,Shufang Wang,Stefanie Mason,Eddie Darton,Louise R. Rodino‐Klapac	2023	1
9	P17 Safety and efficacy of pre-treatment with imlifidase prior to AAV-based gene therapy in non-human primates with pre-existing anti-AAVrh74 antibodies Neuromuscular Disorders ·Rachael A. Potter,S A Khan,Jenna Snedeker,K. Adegboye,Alex Haile,Behnam Sayanjali,N. Pukos,Kyle R. Cochran,J. Ahner,Tung‐Hung Su,Néstor L. Uzcátegui,Yvonne Stenberg,C. Freiburghaus,Lena Winstedt,Louise R. Rodino‐Klapac	2023	1
10	Long-term Safety and Efficacy in Patients with DMD 4 Years Post-Treatment with Delandistrogene Moxeparvovec (SRP-9001) in a Phase 1/2a Study (P3-8.006) Neurology ·J. Mendell,Zarife Sahenk,Kelly J. Lehman,Linda Lowes,Natalie F. Reash,M. Iammarino,Lindsay N. Alfano,Sarah Lewis,Kathleen Church,Richard Shell,Rachael A. Potter,Danielle Griffin,Mark Hogan,Shufang Wang,Stefanie Mason,Eddie Darton,Louise R. Rodino‐Klapac	2023	2
11	Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy Frontiers in Cell and Developmental Biology ·Jerry R. Mendell,Perry B. Shieh,Craig M. McDonald,Zarife Sahenk,Kelly J. Lehman,Linda Lowes,Natalie F. Reash,M. Iammarino,Lindsay N. Alfano,Brenna Sabo,Jeremy D. Woods,Christy Skura,Howard C. Mao,Loretta A. Staudt,Danielle A. Griffin,Sarah J. Lewis,Shufang Wang,Rachael A. Potter,Teji Singh,Louise R. Rodino‐Klapac	2023	42
12	Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model Molecular Therapy — Methods & Clinical Development ·Young-Eun Seo,Stephen Baine,Amber Kempton,Oliver C. Rogers,Sarah Lewis,Kaitlin Adegboye,Alex Haile,Danielle A. Griffin,Ellyn L. Peterson,Eric R. Pozsgai,Rachael A. Potter,Louise R. Rodino‐Klapac	2023	10
13	A Phase 2 Clinical Trial Evaluating the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD) (S48.004) Neurology ·Jerry R. Mendell,Perry B. Shieh,Zarife Sahenk,Kelly J. Lehman,Linda Lowes,Natalie F. Reash,M. Iammarino,Lindsay N. Alfano,Brenna Sabo,Jeremy Woods,Christy Skura,Howard Mao,Loretta A. Staudt,Rachael A. Potter,Danielle Griffin,Sarah J. Lewis,Shufang Wang,Tejdip Singh,Louise R. Rodino‐Klapac	2023	4
14	Phase 1/2a Trial of SRP-9001 in Patients with Duchenne Muscular Dystrophy: 3-Year Safety and Functional Outcomes (S23.004) Neurology ·Jerry R. Mendell,Zarife Sahenk,Kelly J. Lehman,C. Nease,Linda Lowes,Natalie F. Reash,M. Iammarino,Lindsay N. Alfano,J. Vaiea,Sarah Lewis,Kathleen Church,Richard Shell,Rachael A. Potter,Danielle A. Griffin,Eric R. Pozsgai,Mark Hogan,Larry Hu,Kathryn Giblin,Louise R. Rodino‐Klapac	2022	1
15	Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy Human Gene Therapy ·Rachael A. Potter,Danielle A. Griffin,Kristin N. Heller,Ellyn L. Peterson,Emma K. Clark,Jerry R. Mendell,Louise R. Rodino‐Klapac	2021	51
16	A Multicenter Randomized, Double-Blind, Placebo-Controlled, Gene-Delivery Clinical Trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne Muscular Dystrophy (4478) Neurology ·Jerry R. Mendell,Perry B. Shieh,Zarife Sahenk,Kelly J. Lehman,Linda Lowes,N. Miller,M. Iammarino,Lindsay N. Alfano,Jeremy Woods,Christy Skura,Howard Mao,Loretta A. Staudt,Rachael A. Potter,Danielle Griffin,Sarah Lewis,Larry Hu,Sameer Upadhyay,Teji Singh,Louise R. Rodino‐Klapac	2021	2
17	Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy Human Gene Therapy ·Danielle A. Griffin,Eric R. Pozsgai,Kristin N. Heller,Rachael A. Potter,Ellyn L. Peterson,Louise R. Rodino‐Klapac	2020	16
18	Clinical development on the frontier: gene therapy for duchenne muscular dystrophy Expert Opinion on Biological Therapy ·Damon R. Asher,Khampaseuth Thapa,Sachi D. Dharia,Navid Khan,Rachael A. Potter,Louise R. Rodino‐Klapac,Jerry R. Mendell	2020	59
19	Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy Human Gene Therapy ·Rachael A. Potter,Danielle A. Griffin,Patricia Sondergaard,R.W. Johnson,Eric R. Pozsgai,Kristin N. Heller,Ellyn L. Peterson,Kimmo Lehtimäki,Hillarie Plessner Windish,Plavi Mittal,Douglas E. Albrecht,Jerry R. Mendell,Louise R. Rodino‐Klapac	2017	41
20	Suppression of protein kinase C theta contributes to enhanced myogenesis In vitro via IRS1 and ERK1/2 phosphorylation BMC Cell Biology ·Joseph Marino,Terry D. Hinds,Rachael A. Potter,Eric Ondrus,Jeremy L Onion,Abigail R. Dowling,Thomas J. McLoughlin,Edwin R. Sánchez,Jennifer W. Hill	2013	13

About Rachael A. Potter

Rachael A. Potter is a scholar working on Genetics, Business and International Management and Molecular Biology, having authored 30 papers that have together received 667 indexed citations. Recurring topics across this work include Muscle Physiology and Disorders (27 papers), Virus-based gene therapy research (15 papers), Tissue Engineering and Regenerative Medicine (6 papers), CAR-T cell therapy research (6 papers), Viral Infections and Immunology Research (4 papers), Prosthetics and Rehabilitation Robotics (3 papers), Neurogenetic and Muscular Disorders Research (3 papers) and GDF15 and Related Biomarkers (3 papers). The work is most often cited by research in Genetics (129 citations), Genetics (272 citations) and Molecular Biology (581 citations). Rachael A. Potter has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Louise R. Rodino‐Klapac, Danielle A. Griffin, Jerry R. Mendell, Kelly J. Lehman, Eric R. Pozsgai, Sarah Lewis, Zarife Sahenk, Linda Lowes, M. Iammarino and Lindsay N. Alfano. Their work appears in journals such as Nature Medicine, SHILAP Revista de lepidopterología and Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact